- Home
- ANAB vs NVGS Comparison
ANAB vs NVGS Comparison
Compare ANAB & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | NVGS |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ANAB | NVGS |
|---|---|---|
| Price | $54.57 | $20.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $71.67 | $21.50 |
| AVG Volume (30 Days) | ★ 723.1K | 391.2K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.30% |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.14 | N/A |
| P/E Ratio | ★ N/A | $13.06 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $14.08 |
| 52 Week High | $73.30 | $24.36 |
Technical Indicators
Market Signals| Indicator | ANAB | NVGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 46.25 |
| Support Level | $54.23 | $17.38 |
| Resistance Level | $57.70 | $21.36 |
| Average True Range (ATR) | 3.31 | 0.64 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 57.04 | 30.73 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.